SEARCH FILTERS
Time filter
Source Type

News Article | May 17, 2017
Site: marketersmedia.com

— Market Highlights The global genetic testing market has been evaluated as rapidly growing and is expected to grow further. Benefits such as predicting risk of diseases, genetic abnormalities along with prenatal and newborn congenital abnormalities etc. had increased the market of global genetic testing globally. Global genetic testing market is growing rapidly post 2016 due to an increasing number of cases of newborn, prenatal and other molecular abnormalities. This market size is expected to increase by USD of 8.8 billion by the end of 2022. Global Genetic Testing Market is expected to grow at 9.6% CAGR From 2016-2022 Key players of Global Genetic Testing Market: • Abbott (U.S.) • AutoGenomics (Ireland) • Biocartis (Switzerland) • Bio-Rad (U.S.) • Cepheid (U.S.) • EKF Diagnostics (U.K.) • Elitech Group (France) • IntegraGen (France) • Interpace Diagnostics (U.S.) • Myriad Genetics (U.S.) • Perkin Elmir (U.S.A.) • Quest Diagnostic (U.S.) • Roche Diagnostic • WaferGen Biosystem and others With technological advancement in recent years, the genetic testing device market has become one of the most important market in the healthcare industry. Genetic testing allows diagnosis of any disease as well as predicting its risk of affecting any individual. Genetic testing helps in delivering customized health services to the patient hence is also known as personalized medicine. It allows in determining bloodlines, diseases, inherited disorders and even gender and health of the fetus. Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Genetic Testing Market Research Report- Global Forecast To 2022’’ Commenting on this report, an analyst from Market Research Future (MRFR)’s team said: “The market for genetic testing is growing rapidly due to increasing demand of newborn and prenatal screening to detect congenital abnormalities and other molecular disorder; moreover these are expected to continue their growth in the coming future. There are various factors and opportunities which help the global genetic testing market to grow, major driving factors includes innovations and technological advancements for diagnosing as well as increasing cases of prenatal and newborn congenital abnormalities. Some factors which hamper the growth of genetic testing market is high cost involved in the research and development process required for developing new technologies. Segments: Based on methods of testing • cytogenetic, • biochemical • molecular. Based on techniques used in screening • PCR, • southern blotting, • ligation and others. on the basis of application • screening, • diagnostic testing, • prenatal testing, • forensic testing, • parental testing and others. Similarly on the basis of end users • hospitals • research labs and centers • institutions and others etc. List of Tables Table 1 Global Genetic Testing Market, By Methods, 2013-2022 (Usd Million) Table 2 Global Genetic Testing Market, By Techniques, 2013-2022 (Usd Million) Table 3 Global Genetic Testing Market By Application 2013-2022 (Usd Million) Table 4 Global Genetic Testing Market, By End Users 2013-2022 (Usd Million) Continue…. List of Figures Figure 1 Research Process Figure 2 Porters Five Forces Model Figure 3 Global Genetic Testing Market Market, By Methods Figure 4 Global Genetic Testing Market, By Techniques Figure 5 Global Genetic Testing Market, By Application Continue…. Related Report Global Organic Baby Food Market Information- by Ingredient (fruits, vegetables, grains & cereals, meat, and dairy), by Product type (baby milks, baby cereals dry meals, finger foods, baby drinks & other organic baby foods), by Region - Forecast to 2027. Know more about this report @ https://www.marketresearchfuture.com/reports/organic-baby-food-market About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com


The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of hsa-miR-31-5p (SEQ ID NO:2) miRNA in a sample of said patient. The invention also relates to kits for measuring the expression of hsa-miR-31-5p and at least one other parameter positively or negatively correlated to response to EGFR inhibitors. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.


Integragen est une société spécialisée dans le décryptage du génome humain, et réalise des analyses pertinentes et rapidement interprétables pour des laboratoires académiques et privés. Dans l’oncologie, qui se caractérise par un dérèglement génétique des cellules cancéreuses, IntegraGen fournit aux chercheurs et aux médecins des outils universels et individualisés de guidage thérapeutique leur permettant d’adapter le traitement au profil génétique du patient.


News Article | September 28, 2017
Site: www.businesswire.com

A propos d’IntegraGen IntegraGen est une société spécialisée dans le décryptage du génome humain, et réalise des analyses pertinentes et rapidement interprétables pour des laboratoires académiques et privés. Dans l’oncologie, qui se caractérise par un dérèglement génétique des cellules cancéreuses, IntegraGen fournit aux chercheurs et aux médecins des outils universels et individualisés de guidage thérapeutique leur permettant d’adapter le traitement au profil génétique du patient.


The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of hsa-miR-31-5p (SEQ ID NO:2) miRNA in a sample of said patient. The invention also relates to kits for measuring the expression of hsa-miR-31-5p and at least one other parameter positively or negatively correlated to response to EGFR inhibitors. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.


The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of at least one target gene of hsa-miR-31-3p (SEQ ID NO:1) miRNA in a sample of said patient, wherein said target gene of hsa-miR-31-3p is selected from DBNDD2 and EPB41 L4B. The invention also relates to kits for measuring the expression of DBNDD2 and/or EPB41 L4B and at least one other parameter positively or negatively correlated to response to EGFR inhibitors. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.


Patent
IntegraGen, French Institute of Health, Medical Research, French National Center for Scientific Research, Assistance Publique Hopitaux De Paris and University of Paris Descartes | Date: 2012-11-23

The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.


Patent
IntegraGen, French Institute of Health, Medical Research and University of Paris Descartes | Date: 2013-09-23

The present invention relates to the technical field of liver diseases, their classification and diagnosis. It provides a new method for classifying a liver sample between non-hepatocellular sample; hepatocellular carcinoma (HCC) sample with further classification into one of subgroups G1 to G6; focal nodule dysplasia (FNH) sample; hepatocellular adenoma (HCA) sample with further classification into HNF1A mutated HCA, inflammatory HCA, catenin mutated HCA or other HCA sample; and other benign liver sample, based on determination in vitro of genes expression profiles and analysis of the expression profile using algorithms calibrated with reference samples. The invention also provides kits for the classification of liver samples, and methods of treatment of liver disease in a subject based on a preliminary classification of a liver sample of said subject.


The present invention relates to the technical field of hepatocellular carcinoma (HCC) management, and more precisely to the prognosis of HCC aggressiveness and associated therapeutic decisions. The invention provides a new prognosis method of HCC aggressiveness, based on determination in vitro and analysis of an expression profile comprising genes TAF9, RAMP3, HN1, KRT19, and RAN. The invention also provides kits for the prognosis of HCC aggressiveness, and methods of treatment of HCC in a subject based on a preliminary prognosis of said subject HCC aggressiveness.


Patent
IntegraGen | Date: 2013-03-08

The invention relates to a method of determining a risk of, or of detecting the predisposition to or the presence of autism in a subject, the method comprising detecting the combined presence of risk-associated SNP alleles at multiple loci in a sample from said subject, which method comprises genotyping a single nucleotide polymorphism (SNP) in the gene loci of at least HTR5A, MACF1, RBFOX1, ABR, PTPRG, CACNA2D1, GFRA1, DSCAML1, CHRM3, LPPR4, DLG2, SLC9A9 and BASP1.

Loading IntegraGen collaborators
Loading IntegraGen collaborators